Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XURIDEN vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
Emergency treatment of fluorouracil (5-FU) overdose,Emergency treatment of capecitabine overdose
Treatment of hypophosphatemia,Total parenteral nutrition (TPN) additive,Phosphate replacement in patients with phosphate depletion
60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h). Clinically relevant for dosing interval (every 6 hours).
Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation.
Xuriden is deacetylated by esterases in the plasma and tissues to release uridine, which is then further metabolized via the pyrimidine salvage pathway.
Phosphate is freely filtered by the glomerulus and reabsorbed in the proximal tubule; excess is excreted renally. No significant hepatic metabolism.
Renal: predominantly as intact uridine (47-62%) and uracil (16-25%); fecal/biliary: minimal (<5%).
Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss.
<5% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Phosphate: 10-15% bound to serum proteins (albumin and immunoglobulins). Potassium: <5% protein bound.
Vd: 0.5-0.8 L/kg, indicating distribution into total body water.
Phosphate: 0.15-0.3 L/kg (primarily extracellular fluid). Potassium: 0.5-0.7 L/kg (distributes into intracellular space).
Oral: approximately 60% (range 40-80%) due to first-pass metabolism.
Intravenous: 100% bioavailability. Oral (not applicable for this formulation): 60-70% for phosphate salts; potassium salts >90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
GFR <30 m L/min: initiate at 50% of standard dose and titrate based on serum phosphate and potassium levels; avoid if GFR <15 m L/min unless severe hypophosphatemia.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to potential for electrolyte disturbances.
Weight-based dosing: 60 mg/kg orally once daily. Maximum dose 6000 mg/day. Administer with food.
IV: 0.5-1 mmol phosphate/kg over 12-24 hours; monitor serum phosphate and potassium closely; do not exceed 5 mmol/kg/day.
No specific dose adjustment recommended. Use with caution due to age-related decline in renal function; monitor renal function periodically.
Initiate at lower end of dosing range; monitor renal function and serum electrolytes more frequently due to age-related decline in GFR.
None.
None
Not indicated for non-emergency use or as prophylaxis for chemotherapy.,Should be initiated as soon as possible after overdose, ideally within 96 hours.,May cause diarrhea, nausea, vomiting, and abdominal pain.
Hyperphosphatemia, especially in renal impairment,Hypocalcemia due to precipitation with calcium,Monitor serum calcium, phosphate, and renal function,Avoid extravasation (may cause tissue necrosis),Not for IV push; give as slow infusion
None known.
Hyperphosphatemia,Hypocalcemia,Renal failure (unless on dialysis),Patients with known hypersensitivity to any component
Take with food to minimize gastrointestinal discomfort. No specific food restrictions; avoid excessive grapefruit juice as it may affect uridine metabolism.
Avoid high-phosphate foods (e.g., dairy, nuts, seeds, whole grains, cola) and high-potassium foods (e.g., bananas, oranges, potatoes, spinach) unless prescribed. Limit intake of calcium-rich foods if calcium levels are low.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effects (neural tube defects, skeletal malformations) at doses 0.4 times the human dose based on body surface area. Risk cannot be ruled out. First trimester: potential for major malformations; second and third trimesters: potential for fetal growth impairment and neurodevelopmental effects.
FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalcemia, electrolyte imbalances in fetus; avoid prolonged use.
No data on presence in human milk, effects on breastfed infant, or milk production. Given the molecular weight of uridine triacetate (approximately 488 Da) and its metabolic conversion, excretion into breast milk is plausible. M/P ratio not determined. Use during breastfeeding only if clearly needed and consider alternatives or pump and discard.
Excretion in human milk unknown; M/P ratio not determined. Use with caution, weighing benefit against potential risk of electrolyte disturbances in the nursing infant.
Physiological changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce uridine triacetate exposure. No formal dosing adjustment studies; however, monitor clinical response and consider dose adjustment based on trough levels of uridine or clinical efficacy if available. No specific pregnancy-recommended dose adjustment from manufacturer.
Increased plasma volume may require higher doses to achieve therapeutic levels; monitor serum electrolytes closely to avoid hyperphosphatemia or hypocalcemia. No standard dose adjustment established.
Xuriden (uridine triacetate) is a pyrimidine analog used for hereditary orotic aciduria. Monitor for orotic acid crystalluria; ensure adequate hydration. Administer with food to reduce GI upset. Not recommended for use with fluorouracil or capecitabine due to interference.
Do not administer undiluted; must be infused via central line if concentration > 0.45% potassium phosphate. Monitor serum potassium, phosphate, calcium, and magnesium. Rate of infusion should not exceed 10 mmol/h of phosphate. Risk of hypocalcemia due to phosphate precipitation. Use with caution in renal impairment.
Take exactly as prescribed, usually once daily with food.,Do not crush or chew tablets; swallow whole.,Drink plenty of fluids to prevent kidney stones.,Report any signs of allergic reaction or severe abdominal pain.,Continue treatment even if feeling well; do not stop without consulting physician.
This medication is given through a vein to restore phosphate and potassium levels.,Report any signs of infusion site pain, redness, or swelling.,Inform your healthcare provider if you experience muscle cramps, weakness, numbness, or tingling.,This medication may cause low calcium levels; report symptoms such as muscle spasms or confusion.,Do not consume additional potassium or phosphate supplements unless directed by your doctor.
No interactions on record
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XURIDEN vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE, answered by our medical review team.
XURIDEN is a Metabolic Agent that works by Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XURIDEN and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XURIDEN is: 60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.. The standard adult dose of POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is: IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XURIDEN and POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XURIDEN is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effec. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is classified as Category A/B. FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalce. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.